MX2018012351A - Formulaciones de oxitocina que contienen magnesio y metodos de uso. - Google Patents

Formulaciones de oxitocina que contienen magnesio y metodos de uso.

Info

Publication number
MX2018012351A
MX2018012351A MX2018012351A MX2018012351A MX2018012351A MX 2018012351 A MX2018012351 A MX 2018012351A MX 2018012351 A MX2018012351 A MX 2018012351A MX 2018012351 A MX2018012351 A MX 2018012351A MX 2018012351 A MX2018012351 A MX 2018012351A
Authority
MX
Mexico
Prior art keywords
methods
magnesium
containing oxytocin
administration
magnesium ions
Prior art date
Application number
MX2018012351A
Other languages
English (en)
Inventor
C Yeomans David
Carson Dean
Original Assignee
Trigemina Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trigemina Inc filed Critical Trigemina Inc
Publication of MX2018012351A publication Critical patent/MX2018012351A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/084—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being oxytocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen los métodos y composiciones para el tratamiento del trastorno del espectro del autismo, trastornos relacionados y síntomas de tales trastornos, que comprende la coadministración de un péptido de oxitocina y iones de magnesio. La coadministración de un péptido de oxitocina y los iones de magnesio da como resultado un efecto sinérgico o aumentado sobre la reducción de los déficits sociales y de comunicación en un paciente que sufre de un trastorno del espectro del autismo.
MX2018012351A 2016-04-12 2017-04-12 Formulaciones de oxitocina que contienen magnesio y metodos de uso. MX2018012351A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662321654P 2016-04-12 2016-04-12
PCT/US2017/027265 WO2017180781A1 (en) 2016-04-12 2017-04-12 Magnesium-containing oxytocin formulations and methods of use

Publications (1)

Publication Number Publication Date
MX2018012351A true MX2018012351A (es) 2019-02-07

Family

ID=60041978

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018012351A MX2018012351A (es) 2016-04-12 2017-04-12 Formulaciones de oxitocina que contienen magnesio y metodos de uso.
MX2023008840A MX2023008840A (es) 2016-04-12 2018-10-09 Formulaciones de oxitocina que contienen magnesio y metodos de uso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023008840A MX2023008840A (es) 2016-04-12 2018-10-09 Formulaciones de oxitocina que contienen magnesio y metodos de uso.

Country Status (8)

Country Link
US (1) US20190175686A1 (es)
EP (1) EP3442560A4 (es)
JP (2) JP7093559B2 (es)
CN (2) CN109414476B (es)
AU (2) AU2017250505B2 (es)
CA (1) CA3020179A1 (es)
MX (2) MX2018012351A (es)
WO (1) WO2017180781A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020288999A1 (en) * 2019-06-07 2022-02-03 Paxmedica, Inc. Compositions and methods for treating central nervous system disorders
WO2022167978A1 (en) * 2021-02-03 2022-08-11 Sun Pharmaceutical Industries Limited Oxytocin ready to infuse dosage form

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2938891A (en) 1956-03-30 1960-05-31 Roussel Uclaf Method of making oxytocin and intermediates thereof
US3076797A (en) 1957-07-22 1963-02-05 Roussel Uclaf Process of producing oxytocin and intermediates obtained thereby
DE19627228A1 (de) 1996-07-05 1998-01-08 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung für Medien
US5798266A (en) * 1996-08-27 1998-08-25 K-Quay Enterprises, Llc Methods and kits for obtaining and assaying mammary fluid samples for breast diseases, including cancer
US20070032410A1 (en) 2000-01-11 2007-02-08 Atossa Healthcare, Inc. Compositions and methods for the treatment of psychiatric disorders
KR20040058324A (ko) * 2001-11-26 2004-07-03 다이이찌 산토리 파마 가부시키가이샤 경비흡수용 의약 조성물
GB0209494D0 (en) 2002-04-25 2002-06-05 Optinose As Nasal devices
CA2500831A1 (en) 2002-10-03 2004-04-15 Eric Hollander Treatment of autism and similar disorders
GB0319119D0 (en) 2003-08-14 2003-09-17 Optinose As Delivery devices
DE602006012513D1 (de) * 2005-08-26 2010-04-08 Healthpartners Res Foundation Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin
KR101728868B1 (ko) * 2006-01-18 2017-05-02 포시 파마슈티컬스 컴퍼니 리미티드 안정성이 강화된 약학 조성물
US9023793B2 (en) 2006-09-29 2015-05-05 Retrophin, Inc. Intranasal carbetocin formulations and methods for the treatment of autism
US20080249178A1 (en) 2007-03-22 2008-10-09 Guosong Liu Magnesium compositions and uses thereof for increasing lifespan
CN101677948A (zh) * 2007-06-07 2010-03-24 纳斯泰克制药公司 卡贝缩宫素鼻用制剂和治疗孤独症的方法
US20130130985A1 (en) 2010-04-01 2013-05-23 Paul Alewood Oxytocin peptide analogues
JO3400B1 (ar) 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
EP2845850A1 (en) * 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists

Also Published As

Publication number Publication date
CN109414476A (zh) 2019-03-01
MX2023008840A (es) 2023-08-14
EP3442560A1 (en) 2019-02-20
EP3442560A4 (en) 2020-03-04
WO2017180781A1 (en) 2017-10-19
CA3020179A1 (en) 2017-10-19
AU2023203831A1 (en) 2023-07-13
AU2017250505A1 (en) 2018-11-08
CN109414476B (zh) 2023-01-31
JP2022079671A (ja) 2022-05-26
JP2019513765A (ja) 2019-05-30
US20190175686A1 (en) 2019-06-13
AU2017250505B2 (en) 2023-03-30
CN115814055A (zh) 2023-03-21
JP7093559B2 (ja) 2022-06-30

Similar Documents

Publication Publication Date Title
AU2015339284A8 (en) Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
MX2023000482A (es) Composiciones y metodos para inhibir la masp-3 para el tratamiento de diferentes enfermedades y trastornos.
MX2020001774A (es) Composiciones y métodos para tratar enfermedad colestásica.
MX2019003363A (es) Composiciones farmaceuticas para usarse en la terapia de la blefaritis.
MX2019004500A (es) Terapia de combinación para la inhibición de componente de complemeto (c3).
MY179105A (en) Methods of treating alzheimer's disease
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
MX2018008105A (es) Compuestos inhibidores de metaloenzima.
WO2016077639A3 (en) Nanovesicular therapies
MX2018005233A (es) Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer.
EP4331670A3 (en) Magnesium-containing oxytocin formulations and methods of use
PH12017501028A1 (en) Treatment of retinal degeneration using progenitor cells
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
PH12020500079A1 (en) Novel substituted xanthine derivates
PH12020551071A1 (en) Compositions and methods for treating retinal disorders
AU2016298962A8 (en) Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
PH12016501838A1 (en) Compounds and their methods of use
MX2023008840A (es) Formulaciones de oxitocina que contienen magnesio y metodos de uso.
MX2022013283A (es) Composiciones para limpieza de colon y tratamiento de trastornos gastrointestinales.
PH12020551331A1 (en) Treatment and prevention of pre-eclampsia
NZ737410A (en) Compositions comprising anakinra
MX2017003892A (es) Tratamiento del sindrome de rett.
NZ724799A (en) Compositions and methods for the treatment or prevention of neurodegenerative disorders
MX2019013207A (es) Metodos y composiciones para tratar la endometriosis y sintomas asociados a la endometriosis.
NZ747201A (en) (+)-azasetron for use in the treatment of ear disorders